Industry Demands Rethink Of German HTA Data Requirements
Executive Summary
The pharmaceutical industry is calling for more flexible evidence requirements for health technology assessments in Germany after the country’s HTA body, IQWiG, claimed that too many new products entering the market lack additional benefit.
You may also be interested in...
German HTA Body Slams Lack Of 'Real Innovation'
Too many new drugs have the same mechanism of action, says Germany’s health technology appraisal institute, IQWiG.
European Commission HTA Proposals Should Mandate Comparative Trials, Says Germany
Pharmaceutical companies should be obliged to carry out comparative trials, according to analysis from Germany’s Institute For Quality and Efficiency in Healthcare, IQWiG.
Germany To Increase Data Requirements For Pricing Orphan And Other Drugs
A new bill going through the German legislative process could oblige manufacturers of orphan drugs and certain other products to submit real-world data from registries that would impact pricing.